Sanofi Q3 sales up, business net income $2,141

Sanofi’s Q3 2017 sales performance were supported by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets, and it saw net sales at €9,053 million, up 0.3% on a reported basis and 4.7% at CER reflecting the change in scope of the CHC and Vaccines Global Business Units (GBUs). At CER and CS(3), net sales were stable (-0.2%).

The company reported business net income for the Q3 2017 at $2,141 M, compared to the same period last year of $2,300 M.

Sanofi Genzyme grew 13.9% at CER due to the strong U.S. launch of Dupixent and good growth in Multiple Sclerosis. Sanofi Pasteur grew 7.2% at CER and CS largely driven by pediatric combinations and booster vaccines.

Sanofi Chief Executive Officer, Olivier Brandicourt, said: “The strong launch of Dupixent in the U.S., the continued double-digit growth of our Multiple Sclerosis franchise and the performance of our pediatric vaccines were important drivers in the quarter. These positive dynamics, accompanied by robust growth in Emerging Markets and disciplined expense management, offset the decline of our Diabetes franchise. We are pleased by the progress in R&D demonstrated by the positive phase 3 topline results in asthma for Dupixent® and the recent advances of cemiplimab, our anti PD-1, in oncology.”

Featured image: A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo